Chapter 54: Drugs for Sexual Dysfunction

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

You know, when you're troubleshooting a computer that keeps crashing, you basically have to ask yourself one fundamental question before you do anything else.

Right.

Like, is it the hardware or the software?

Exactly.

Is the physical hardware actually failing or did a recent software update just like corrupt the whole system?

It's a strict process of elimination.

And honestly, diagnosing sexual dysfunction in a clinical setting is remarkably similar.

It really is.

Yeah.

Welcome to this deep dive.

Today, we're taking the incredibly dense pharmacology of sexual dysfunction, specifically Chapter 54 of Len's Pharmacotherapeutics, and we're translating it into real world patient centered prescribing logic.

Yeah.

So if you are an advanced practice nursing or PA student, consider this your highly focused one on one clinical tutoring session.

It's a critical topic.

Yeah.

But before we start troubleshooting the pathways, we need to establish the clinical parameters we're working within today.

Right.

The authors of our text provide a very specific caveat right at the beginning of the chapter that we need to mention.

Right.

The data limitations.

Exactly.

The current clinical guidelines, and therefore the terminology we'll be using today, they focus on cisgender patients.

Because there just isn't the research yet.

Yeah.

There simply isn't sufficient pharmacological data right now to recommend specific evidence based treatments for trans masculine and trans feminine populations.

So for the purpose of mastering this specific textbook chapter, we're going to be operating within those biologically binary parameters.

It is a crucial baseline to understand as we get into this.

Absolutely.

So let's jump right into that computer analogy.

We're going to look at erectile dysfunction or ED first.

Which by the way, affects up to 30 million men in the US alone.

30 million.

That's huge.

So when a patient presents with ED, we have to figure out if it's a system failure of the hardware or the software.

Right.

If we're looking at the hardware like the physical, vascular, and neurological structures, what are the major culprits there?

Well, the primary hardware issues are chronic illnesses that just damage blood vessels and nerves over time.

Age is a significant factor, obviously.

That's like how significant?

Well, we see it affecting about 4 % of men in their 50s.

But that climbs steeply to nearly half of all men over the age of 75.

Wow.

Half.

Yeah.

But the most destructive hardware issue by far is diabetes.

The incidence of ED among men with diabetes is massive.

It's between 35 and 75%.

That is a staggering statistic.

Why is it so high?

Because diabetes systematically damages the microvascular circulation and the peripheral nerves.

And both of those are absolute prerequisites for achieving an erection.

Okay, so that's the hardware.

But then there's the software side of the equation, which is the patient's daily medication list.

The software updates, right.

Yeah.

And I was completely struck by the sheer volume of drugs that actively induce ED.

Oh, it's wild.

If we look at the clinical data in Table 54 .1, medications are the primary suspect in a huge percentage of these cases.

Yeah.

I think the text said about 25 % of all ED cases are medication -induced.

Exactly.

That is one in four patients whose dysfunction is essentially just a side effect of a prescription.

Which is crazy.

So the immediate clinical takeaway here for you as a prescriber is that your first -line treatment isn't always, you know, writing a new prescription for a pill to fix the problem.

Right.

Often the most effective intervention is a lifestyle measure like smoking cessation or simply removing the offending drug.

Let's talk about those offending drugs, actually, because the list spans almost every major drug class.

It really does.

You have cardiovascular drugs like thiazide diuretics, which reduce blood volume and clonidine.

You have digoxin, which causes sexual dysfunction in like 36 % of patients.

And then you have the central nervous system drugs.

So SSRIs, tricyclic antidepressants, antipsychotics,

all of these alter the specific neurotransmitters required for arousal.

Even finasteride, right?

The five -alpha reductase inhibitor.

Yeah.

Used for enlarged prostates or hair loss.

That causes ED in roughly a third of users.

And we absolutely cannot ignore alcohol.

No, we cannot.

Alcohol is implicated in 50 to 75 % of cases.

Because it's a massive central nervous system depressant, right?

Exactly.

It blunts the very neurological signals required to initiate the vascular cascade we're about to discuss.

So a meticulous medication and substance reconciliation is always step one.

Because if we don't fix the software, adding more drugs is just fighting a losing battle.

Totally.

So let's say we've done that thorough reconciliation.

To understand how we therapeutically intervene with drugs, we have to understand the underlying physiological machinery first.

The plumbing, basically.

Yeah, the plumbing.

I want to break down this pathway from figure 54 .1.

Because it's essentially a very elegant, highly localized hydraulic system.

And it starts in the brain, right?

It does.

The entire cascade begins with sexual arousal.

Without that initial psychological and tactile trigger, the physiological machinery just stays dormant.

So arousal increases parasympathetic nerve traffic down to the penis.

Right.

And that nerve traffic prompts the local release of a vital molecule, which is nitric oxide, or NO.

And that nitric oxide is the chemical messenger that turns the system on.

It activates an enzyme called guanylyl cyclis.

Think of guanylyl cyclis as a little manufacturing plant.

Okay, I like that.

Once it's activated by nitric oxide, it starts churning out a compound called cyclic guanosine monophosphate.

CGMP for short.

Yes, CGMP is the star of the show here.

It's a really powerful vasodilator.

So it promotes the relaxation of the arterial and trabecular smooth muscle in the penis.

Exactly.

And when that smooth muscle relaxes, the arteries dilate wide open, drastically increasing local blood flow and pressure.

The sinusoidal spaces in the corpus cavernosum basically engorge with blood.

And here's where the hydraulic lock happens.

The trap door.

Right.

As those spaces expand and fill with arterial blood, they physically press against the veins that normally drain blood out of the penis.

It mechanically compresses them, causing venous occlusion.

So you have massively increased inflow and mechanically blocked outflow.

The blood is trapped, resulting in an erection.

And that erection naturally subsides when the body releases an enzyme to clean up the CGMP.

Right, kind of acting like a janitor.

Exactly.

That enzyme is phosphodiesterase type 5, or PDE5.

It breaks down the CGMP into an inactive state.

And then the smooth muscle regains its tension, the arteries constrict, the veins open back up, and detumescence occurs.

You've got it perfectly.

OK, so if CGMP is the water filling the tub, PDE5 is the open drain pulling the water out.

I love that analogy.

Thanks.

So the oral drugs we prescribe, the PDE5 inhibitors, they essentially act as a rubber stopper for that drain.

Yep.

By blocking the enzyme, the CGMP stays in the system longer, maintaining the erection.

Now, from a purely logical standpoint, it seems obvious that we would just hand out these PDE5 inhibitors as the default first step for every single patient.

You would think so.

Right.

But when you look at the American Urological Association's Treatment Algorithm Figure 54 .2 in the text, it explicitly does not mandate a step therapy approach.

No, it doesn't.

We don't have to start with pills.

Why the lack of a rigid staircase there?

Well, the AUA guidelines are a fantastic example of genuine shared decision making.

They recognize that sexual dysfunction is deeply personal and really impacts a patient's relationship dynamics.

So it's not a one size fits all.

Exactly.

Rather than forcing a patient to fail on a pill before trying something else, they offer a full menu of options as first -line therapies right out of the gate.

Oh wow.

So a patient can choose PDE5 inhibitors, but they can also immediately opt for vacuum constriction devices,

or intra -cavernosal injections, or even penile prosthesis surgery.

Right.

The choice is dictated entirely by the values, the priorities, and the acceptable risk profile of the man and his partner.

I really appreciate that patient -centered framework.

But I mean, the reality of clinical practice is that oral PDE5 inhibitors are by far the most commonly utilized option.

Oh, without a doubt.

So we need to know them inside and out.

Looking at tables 54 .2 and 54 .3, we have four main players, sildenafil, tedalafil, bordenafil, and avanafil.

Sildenafil brand name Viagra has that famous origin story.

Oh yeah.

I love this.

It was originally developed as a cardiac medicine to treat angina, right?

Yeah, and it completely failed at that.

But during the trials, the male test subjects reported a very specific, undeniable side effect.

Right.

But here is the critical physiological question for our listeners.

Since the drug only preserves the CGMP by plugging the drain, does that mean the drug is completely useless if the patient isn't sexually aroused in the first place?

That is perhaps the single most vital piece of patient education you can provide.

Yes, it is useless without arousal.

Because PDE -5 inhibitors only enhance a normal erectile response.

Exactly.

They do absolutely nothing in the absence of sexual stimuli.

They are not magic pills that artificially force an erection.

So if there's no erotic imagery, fantasy, or physical contact to trigger that initial parasympathetic release of nitric oxide.

Then there's no CGMP produced.

And if there is no CGMP produced, the drug has nothing to preserve.

You cannot plug a drain and expect the tub to fill if you never turn the thosadone.

That is a guaranteed exam question right there.

Absolutely.

Now, we have to talk safety.

Because manipulating vascular smooth muscle is inherently dangerous.

What are the major cardiovascular red flags?

Well, the physical exertion of sex itself is a primary consideration for patients with severe coronary heart disease.

Right.

Of course.

But from a purely pharmacological standpoint,

the absolute non -negotiable contraindication for PDE -5 inhibitors is concurrent use of nitrates like nitroglycerin.

Let's visualize why that is so deadly.

It's basically a blood pressure seesaw.

Nitrates work by heavily increasing the formation of CGMP to dilate vessels and lower blood pressure.

So nitrates are basically slamming the gas pedal on CGMP production.

Meanwhile, the PDE -5 inhibitor is cutting the brake line by preventing its breakdown.

So you're flooding this system from both ends.

Exactly.

And the result is a profound, uncontrolled, and potentially life -threatening drop in blood pressure.

That's terrifying.

So what's the clinical rule there?

The clinical rule is strict.

A patient must wait at least 24 hours after taking sildenafil or vardenafil before they can safely use a nitrate.

Good to know.

And prescribers also need to use extreme caution with alpha blockers like doxazosin, which also independently lower blood pressure.

Okay.

Aside from the cardiovascular collapse, what are the localized emergencies we need to worry about?

Priapism is the most severe localized risk.

That's the painful sustained erection, right?

Yes, lasting longer than four hours.

It is a true medical emergency.

If blood sits in the corpus cavernosum for hours, it becomes deoxygenated.

And if left untreated?

If left untreated beyond 24 hours, the lack of oxygen causes permanent tissue necrosis and irreversible fibrosis.

Meaning a permanent loss of erectile function.

Exactly.

It requires immediate intervention in the ER, usually involving a needle to aspirate the trapped blood and irrigating the area with a vasoconstrictor to force the vessels closed.

Wow.

Okay, there are also some bizarre, rare sensory risks that patients need to be warned about, They are rare, but yes, serious.

We see cases of non -arteritic ischemic optic neuropathy, or NAION.

What exactly is that?

It's an irreversible blurring or total loss of vision caused by a blockage of blood flow to the optic nerve.

Irreversible.

Wow.

Yeah.

There is also a documented risk of sudden hearing loss, often accompanied by dizziness and tinnitus.

So the counseling point is simple.

If a patient experiences sudden vision or hearing changes, they must stop the medication and seek emergency care instantly.

Absolutely.

Okay, let's differentiate these four drugs.

Because a prescriber needs to know which tool to reach for.

Sildenafil is our classic prototype.

What is the defining characteristic of Tadalafil?

Tadalafil stands out purely because of its half -life.

Sildenafil, Verdinafil, and Avantafil generally provide a duration of action around four hours.

But Tadalafil is longer.

Much longer.

Tadalafil's effects can last up to 36 hours.

36 hours?

Yeah, it essentially stays in the system through an entire weekend.

Because of this extended window, it's the only one in the class approved for daily continuous dosing.

But there's a safety warning with that, right?

Yes.

Yeah.

A crucial one.

Because it lasts so long, if a patient on Tadalafil experiences chest pain and needs a nitrate, they must wait a full 48 hours, not just 24.

That's a huge distinction.

Okay, and if a patient values spontaneity over duration, they'd look at Avantafil.

Correct.

Avantafil has the fastest onset of action.

It can be taken approximately 15 to 30 minutes before sexual activity.

Whereas the others require planning about an hour in advance.

Right.

And the last one, Bardenafil.

That one has a very specific cardiac warning.

It does.

Bardenafil uniquely prolongs the QT interval on an EKG.

Therefore, it is strictly contraindicated for men who are taking class IA or class III antidisrhythmic drugs.

Got it.

Now, here is where patient education intersects with daily life.

Food and drinks.

Oh, this is so important.

If a patient takes sildenafil, bardenafil, or avanafil with a high -fat meal like, say, heavy steak dinner, the absorption is severely delayed.

Yeah, the onset of sildenafil can be pushed back by a full 60 minutes.

Sildenafil is the only one immune to the high -fat meal effect, right?

Correct.

But the real danger is in the beverage aisle.

What is the deal with grapefruit juice?

Grapefruit juice is a potent inhibitor of the CYP3A4 isoenzyme in the liver and intestines.

I always think of the CYP3A4 enzyme as the body's molecular garbage disposal for these specific drugs.

It breaks them down so they can be cleared.

And grapefruit juice essentially unplugs the garbage disposal.

All of these PDE5 inhibitors rely on CYP3A4 for their metabolism.

If you inhibit that enzyme with grapefruit juice, the drug isn't cleared.

It just accumulates in the bloodstream.

Right.

Driving the drug levels up to toxic, dangerous concentrations,

massively increasing the risk of hypotension and priapism,

grapefruit juice must be entirely avoided.

Okay, so if oral medications are out of the question, let's say our patient has severe angina and absolutely relies on their daily nitroglycerin.

Where do we go next?

Because the physiological system still needs that smooth muscle relaxation.

Right.

This brings us to the second line, non -oral agents,

elprosadil and the compounded popperverting mintolami mixture.

Second line for a reason.

Yeah, I have to be honest on behalf of anyone listening,

given the absolute convenience of swallowing a pill, how do you realistically guide a patient toward putting a suppository directly into their urethra or voluntarily injecting a needle into the side of their penis?

It sounds incredibly invasive, I know, but you have to consider the psychological weight of the dysfunction and the lack of alternatives for some patients.

Okay, fair point.

Elprosadil is essentially synthetic prostaglandin E1.

Unlike the oral pills that merely preserve CGMP, elprosadil acts directly on the smooth muscle to force relaxation and cause rapid arterial inflow.

So because it acts locally, it bypasses the systemic hypotension risks associated with the oral meds and nitrates.

Exactly.

Let's talk about the mechanics of administration, starting with the transurethral route.

The brand name there is MEWS.

It involves a tiny pellet that the patient pushes about an inch and a half into the urethra using a plastic applicator.

Sounds uncomfortable.

It can be.

The drug absorbs through the urethral mucosa and diffuses into the corpus cavernosum, producing an erection in about five to 10 minutes.

What are the drawbacks?

Well, the major drawback is discomfort.

Patients frequently report a dull, persistent ache in the penis or urethral burning.

And the alternative is the direct injection.

Yes, intercavernosal injection under the brand name CAVERGECT.

The patient uses a very fine needle to inject the drug directly into one side of the corpus cavernosum.

Does it hurt?

It's remarkably effective and surprisingly painless due to the fine needle, but the dosing regimen is incredibly strict to prevent tissue damage.

Like how strict?

It cannot be used more than three times a week and never more than once in a 24 -hour period.

What happens if they overdo the injections?

Continuous, repeated trauma to the tissue from the needle, combined with the drug itself, can cause penile fibrosis.

That sounds bad.

It is.

It's the development of hard, fibrotic nodules that physically distort the anatomy.

Yikes.

And then there's that compounded mixture, right?

Yes, of papavirin, which is a direct vasodilator, and fintolamine, an alpha blocker.

But that's not FDA approved.

No, it's highly effective, but not FDA approved.

It carries a notoriously high 10 % risk of priapism.

It's a powerful tool, but one that requires immense caution.

Wow.

Okay, we've spent a lot of time focusing on the plumbing, the vascular challenge of getting blood flow right.

Right.

But what happens when the vascular hardware works perfectly, but the neurological timing is off?

Ah, right.

That brings us to premature ejaculation, or PE.

And there is a massive chasm between the layperson's definition and the clinical reality here.

The gap is huge.

If you ask the general public, the layperson definition of PE is essentially any ejaculation that happens earlier than the patient or partner desires.

Which is pretty broad.

Very.

By that broad, subjective metric, about 30 % of men experience it.

But as prescribers, we use the strict criteria from the International Society of Sexual Medicine.

And those ISSM criteria are incredibly narrow.

Yes, they require ejaculation occurring before or within one minute of vaginal penetration for lifelong PE, a total inability to delay it, and it must cause significant psychological distress or interpersonal difficulty.

Under that strict clinical definition, it only affects about 4 % of the male population.

But for that 4%, the distress is profound.

Physiologically, we know that serotonin is the primary neurotransmitter that delays ejaculation while dopamine and oxytocin stimulate it.

Which means, to treat this, we need to increase serotonin in the central nervous system.

Precisely.

So, are we basically intentionally prescribing the side effect of an antidepressant to treat this timing issue?

We absolutely are.

The AUA guidelines recommend selective serotonin reuptake inhibitors, or SSRIs, as the first -line systemic therapy.

Oh, interesting.

Specifically, peroxetine has shown to be the most effective at delaying ejaculation.

But the clinical pearls for the student here are vital.

The doses we use to treat PE are generally lower than the doses used for clinical depression.

And it's not an as -needed thing, right?

Furthermore, this isn't an on -demand drug like Viagra.

Just like when treating depression, the SSRI requires daily, consistent dosing and takes 2 -3 weeks of buildup in the system to achieve its maximal response.

What if the patient refuses a daily systemic psychiatric medication for a localized sexual issue?

Well, the localized alternative is a topical anesthetic, like a lidocaine or prelocaine cream applied directly to the glands of the penis to reduce sensitivity.

But the irony here is palpable.

We're chemically solving the timing issue by numbing the anatomy, potentially robbing the patient of the actual physical sensation they are trying to prolong.

Yeah, it's definitely a trade -off.

Not to mention the mechanical risks to the partner.

Precisely.

If you aggressively numb the penis, you risk transferring that anesthetic directly to the partner during penetration.

Which would cause numbness for them, too.

Exactly.

This can cause vaginal numbness and significantly delay or prevent the partner's orgasm.

Therefore, condom use is absolutely mandatory when utilizing topical anesthetics.

If the SSRIs and the anesthetics fail, the AUA second -line options include alpha -1 blockers and tramadol.

But I have to highlight a statistic from the text that perfectly captures the frustration of treating PE.

Oh, the acupuncture study.

Yes.

The authors mention a study on acupuncture.

The study technically concluded that acupuncture doubled the time to ejaculation.

Which sounds amazing.

It sounds like a miraculous intervention until you look at the raw numbers.

The time increased from 33 seconds to 65 seconds.

It's a perfect example of a result that is statistically significant on paper, but entirely lacking in clinical satisfaction for the patient in the real world.

Exactly.

This profound neurological aspect—how the brain's neurotransmitters govern the sexual response—brings us to a completely different clinical challenge.

Female sexual dysfunction.

Yes.

Specifically, Female Sexual Interest Arousal Disorder, or FSIA.

The text notes this disorder affects anywhere from 10 % to 40 % of women.

The DSM -5 -TR criteria require persistent distress or interpersonal difficulty lasting for more than six months.

A quick, somewhat grim note from the text here.

There are currently zero FDA -approved medications for female orgasmic disorder, or FOD.

None.

But for FSIA -D, we finally have two approved drugs.

Let's start with the older one, Phlebancerin, brand name Addie Case.

Okay, so how does Addie work?

Phlebancerin operates entirely in the brain.

It's a mixed 5 -HT1A agonist and 5 -HT2A antagonist.

Without getting bogged down in the deep neurochemistry, it essentially attempts to rebalance the neurotransmitter scales, increasing dopamine and norepinephrine, which promotes sexual interest, while decreasing serotonin, which can inhibit it.

And who is it for?

It is exclusively approved for premenopausal women with acquired generalized FSIA that is not caused by a medical condition, a psychiatric condition, or relationship trauma.

I look at the logistics of prescribing Phlebancerin, and frankly, I balk.

Think about the burden on the patient.

It's heavy.

It's a daily pill.

It takes several weeks of continuous use to see any benefit whatsoever.

It costs roughly $960 a month.

It provides zero benefit for postmenopausal women.

And that's not even the hardest part.

Right.

The safety profile is so concerning that prescribers and pharmacies have to be specially certified in a REMS program, a risk evaluation and mitigation strategy, just to dispense it.

What is the black box warning that justifies locking this drug down so tightly?

The black box warning centers on cardiovascular collapse.

Phlebancerin can cause severe hypotension and sudden syncope.

Meaning the patient simply passes out.

Yes.

And this risk is massively, dangerously amplified by two common things, CYP3A4 inhibitors and alcohol.

Ah, the garbage disposal again.

Right.

If a patient takes a moderate or strong CYP3A4 inhibitor, locking that liver garbage disposal, the phlebancerin level spike leading to profound hypotension.

And what about the alcohol interaction?

It is so volatile that the FDA mandates strict timing rules.

Patients must wait at least two hours after having just one or two alcoholic drinks before taking their bedtime dose of phlebancerin.

And if they have more than two drinks?

If they've had three or more drinks, they must skip the dose entirely for that night.

Combining the two is a recipe for sudden syncope.

That is a massive, highly restrictive counseling point for a daily medication.

So how does the newer alternative, Bremelanotide, compare?

Bremelanotide, brand named by Lisi, takes a totally different pharmacological approach.

It's a melanocortin receptor agonist.

And the administration is a complete departure from phlebancerin.

It's not a daily pill.

Right.

It's an injection.

Yes.

It is a subcutaneous injection that the patient administers into their abdomen or thigh at least 45 minutes before anticipated sexual activity.

So it acts a lot faster.

It acts much faster, but it is strictly limited to one dose per 24 hours and a maximum of eight doses per month.

What are the side effects that a student needs to counsel their patient on?

Because I imagine an injection carries its own unique psychological hurdles.

Nausea is the predominant physical hurdle, affecting a massive 40 % of users.

It can also cause a transient rise in blood pressure.

Wow, 40 % is a lot.

Yeah.

But the most unique and potentially distressing adverse effect is hyperpigmentation.

Really?

Yeah.

There is a 1 % chance of permanent darkening of the gums and portions of the skin, particularly in patients who naturally have darker skin to begin with.

Permanent darkening.

Yes.

You have to contextualize that psychological impact.

You are treating a patient already experiencing deep distress about their sexual function and self -image, and you are introducing a drug that carries a risk of permanent facial or gum discoloration.

It requires a very sensitive, thorough informed consent discussion.

Absolutely.

That is not a side effect you gloss over.

So what does this all mean for you, the advanced practice student listening right now?

Right.

Pulling it all together.

Mastering these complex pathways,

understanding the nitric oxide cascade, knowing exactly why the CYP3A4 garbage disposal matters,

respecting the black box warnings for syncope.

It isn't just about memorizing facts to pass your pharmacology board exams.

It's about confidently navigating what are incredibly sensitive, vulnerable, quality of life conversations with your patients.

Exactly.

And executing safe, highly rational, patient -centered prescribing.

And as we close this session, I want to leave you with one final, forward -looking clinical thought to mull over.

Oh, let's hear it.

We started this deep dive by noting the author's admission that current guidelines lack data for transgender patients.

Right.

The caveat.

Given how rapidly the field of gender -affirming hormone therapy is evolving,

therapies that fundamentally and intentionally alter the exact neurovascular and hormonal pathways we've spent this session breaking down,

how will the science of pharmacology be forced to rewrite these highly specific, biologically binary algorithms in the very next edition of this textbook?

It's an incredible, necessary question.

And one that the next generation of prescribers, meaning you, will actively help answer in your future practice.

Something to think about.

Definitely.

Until then, remember the cardinal rule of troubleshooting.

Always rigorously check the software before you assume the hardware is broken permanently.

On behalf of the last -minute lecture team, thank you for joining us for this session.

Keep studying the mechanisms, keep asking the hard questions, and we'll catch you next time.